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ABSTRACT
Background Newborn screening allows novel
treatments for cystic ﬁbrosis (CF) to be trialled in early
childhood before irreversible lung injury occurs. As
respiratory exacerbations are a potential trial outcome
variable, we determined their rate, duration and clinical
features in preschool children with CF; and whether they
were associated with growth, lung structure and function
at age 5 years.
Methods Respiratory exacerbations were recorded
prospectively in Australasian CF Bronchoalveolar Lavage
trial subjects from enrolment after newborn screening to
age 5 years, when all participants underwent clinical
assessment, chest CT scans and spirometry.
Results 168 children (88 boys) experienced 2080
exacerbations, at an average rate of 3.66 exacerbations
per person-year; 80.1% were community managed and
19.9% required hospital admission. There was an
average increase in exacerbation rate of 9% (95% CI
4% to 14%; p<0.001) per year of age. Exacerbation
rate differed by site (p<0.001) and was 26% lower
(95% CI 12% to 38%) in children receiving 12 months
of prophylactic antibiotics. The rate of exacerbations in
the ﬁrst 2 years was associated with reduced forced
expiratory volume in 1 s z scores. Ever having a hospital-
managed exacerbation was associated with
bronchiectasis (OR 2.67, 95% CI 1.13 to 6.31) in chest
CT scans, and lower weight z scores at 5 years of age
(coefﬁcient −0.39, 95% CI −0.74 to −0.05).
Conclusions Respiratory exacerbations in young
children are markers for progressive CF lung disease and
are potential trial outcome measures for novel
treatments in this age group.
INTRODUCTION
The occurrence of respiratory exacerbations is
being used increasingly as an outcome measure for
intervention trials in cystic ﬁbrosis (CF) lung
disease, particularly in relatively healthy infants and
young children with this disorder.1 While exacerba-
tions in older patients are associated with an accel-
erated decline in lung function2 and reduced
quality of life and survival,3 4 the association
between exacerbations in infants and preschool
children and long-term outcomes remains
unknown. Widespread adoption of newborn
screening programmes will allow novel treatments
to be introduced in early childhood before irrevers-
ible lung damage occurs. Despite being a familiar
concept, a widely accepted standard deﬁnition of
exacerbations in young children is lacking. The CF
Foundation Clinical Practice Guidelines required
changes in baseline for at least 3 of 11 parameters,
but these were aimed at older patients.5 The
Epidemiologic Study of CF, which includes
one-third of patients with CF in Canada and the
USA, reported that increased cough and new
crackles were strong predictors of exacerbations in
all age groups, with weight loss also a strong pre-
dictor in those younger than 6 years of age.6 For
‘respiratory exacerbations’ to be a useful and robust
outcome measure in early childhood therapeutic
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Key messages
What is the key question?
▸ What are the characteristics of respiratory
exacerbations in preschool children with cystic
ﬁbrosis (CF) and are they associated with
poorer lung structure and function by age
5 years?
What is the bottom line?
▸ Preschool children with CF had an average of
three to four exacerbations per year, with
frequency increasing with age and lower
respiratory symptoms/signs reported more often
in hospital-managed episodes. At age 5 years
the exacerbation rate in the ﬁrst 2 years of life
was associated with lower forced expiratory
volume in 1 s values and ever being admitted
for a respiratory exacerbation was associated
with an increased risk of bronchiectasis and
lower weight-for-age z scores.
Why read on?
▸ Novel treatments to improve CF care are likely
to be trialled increasingly in early childhood
before irreversible lung injury occurs and
respiratory exacerbations could become
important outcome measures since they may
act as markers for progressive lung disease.
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Table 1 Respiratory exacerbations from enrolment to 5 years of age
Parameters Total number Incidence per person-years IRR 95% CI p Value*
Total respiratory exacerbations (n=2080)
Gender
Boys (n=88) 1123 3.83 1.10 0.93 to 1.30 0.261
Girls (n=80) 957 3.48
Group
BAL (n=84) 1047 3.68 1.01 0.85 to 1.19 0.940
Std (n=84) 1033 3.65
Anti-staphylococcal antibiotic prophylaxis for at least the first year of life
Yes (n=54) 516 2.94 0.74 0.62 to 0.88 0.001
No (n=114) 1564 3.99
Pseudomonas aeruginosa
Ever (n=101) 1293 3.90 1.17 0.99 to 1.38 0.062
Never (n=67) 787 3.34
Maternal smoking
Yes (n=41) 471 3.30 0.87 0.72 to 1.05 0.151
No (n=127) 1609 3.79
Highest parental education level for both parents
Completed year 10 (n=24) 283 3.47 1.00 0.766
Completed secondary education (n=39) 449 3.46 1.00 0.72 to 1.38
Trade (n=76) 946 3.66 1.05 0.79 to 1.39
Completed tertiary education (n=17) 236 3.98 1.14 0.83 to 1.58
Age
0–1 year (n=168) 284 3.02 1.00 0.007
>1–2 years (n=165) 411 3.36 1.11 0.94 to 1.31
>2–3 years (n=161) 412 3.47 1.14 0.96 to 1.37
>3–4 years (n=159) 468 4.10 1.36 1.12 to 1.64
>4–5+ years (n=158) 505 4.20 1.39 1.15 to 1.68
Total exacerbations (n=2080)
QLD (n=60) 735 3.49 <0.001
VIC (n=40) 657 5.14
NSW and SA (n=42) 385 2.85
NZ (n=26) 303 3.22
Exacerbations reported by clinic doctor (n=1263)
QLD (n=60) 568 2.52 <0.001
VIC (n=40) 202 1.21
NSW and SA (n=42) 290 2.03
NZ (n=26) 203 2.02
Total/number children† Incidence per person-years IRR 95% CI p Value*
Respiratory exacerbations resulting in hospital admission (n=413)
Parameters
Boys (n=88) 225/64 0.62 1.11 0.81 to 1.52 0.507
Girls (n=80) 188/69 0.55
Continued
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Table 1 Continued
Parameters Total number Incidence per person-years IRR 95% CI p Value*
Group
BAL (n=84) 227/72 0.64 1.22 0.87 to 1.72 0.240
Std (n=84) 186/61 0.53
Anti-staphylococcal antibiotic prophylaxis for at least the first year of life
Yes (n=54) 100/41 0.47 0.74 0.54 to 1.02 0.066
No (n=114) 313/92 0.63
Pseudomonas aeruginosa
Ever (n=101) 315/92 0.76 2.27 1.61 to 3.19 <0.001
Never (n=67) 98/41 0.34
Maternal smoking
Yes (n=41) 124/36 0.71 1.31 0.97 to 1.77 0.075
No (n=127) 289/97 0.54
Highest parental education level for both parents
Completed year 10 (n=24) 82/18 0.83 1.00 0.385
Completed secondary education (n=39) 82/29 0.51 0.62 0.34 to 1.14
Trade (n=76) 180/62 0.56 0.68 0.38 to 1.21
Completed tertiary education (n=17) 34/13 0.46 0.55 0.27 to 1.14
Age
0–1 year (n=168) 64/46 0.58 1.00 0.778
>1–2 years (n=165) 88/69 0.59 1.01 0.73 to 1.40
>2–3 years (n=161) 95/80 0.66 1.13 0.79 to 1.62
>3–4 years (n=159) 80/68 0.55 0.96 0.66 to 1.38
>4–5+ years (n=158) 86/72 0.55 0.95 0.65 to 1.38
Total exacerbations
QLD (n=60) 183/54 0.71 0.021
VIC (n=40) 102/27 0.60
NSW and SA (n=42) 70/32 0.43
NZ (n=26) 58/20 0.51
Exacerbations reported by clinic doctor
QLD (n=60) 151/51 0.57 0.083
VIC (n=40) 55/21 0.31
NSW and SA (n=42) 66/31 0.40
NZ (n=26) 53/18 0.46
*p Value for Poisson regression test of null hypothesis that incidence rates are equal across categories.
†Total number of exacerbations resulting in hospital admission/number of children having at least one exacerbation resulting in hospital admission.
BAL, bronchoalveolar lavage; IRR, incidence rate ratio; NSW, New South Wales; NZ, New Zealand; QLD, Queensland; SA, South Australia, VIC, Victoria.
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trials, their frequency and clinical features in this age group and
their relationship to long-term clinical outcomes need to be
understood. As part of achieving a standardised deﬁnition of
‘respiratory exacerbations’ in young children it is also important
to include parental observations across varying levels of disease
severity.7
We therefore sought to describe the rate, clinical features and
duration of respiratory exacerbations in children diagnosed with
CF after newborn screening and followed until 5 years of age;
to determine if any features discriminated between mild
(community-managed) and more serious (hospital-admission)
episodes; and to characterise associations with growth and lung
structure and function at age 5 years.
METHODS
Subjects and design
This study was a secondary analysis of the Australasian CF
BronchoAlveolar Lavage randomised controlled trial (RCT)
involving eight CF centres (Australian Clinical Trials Registry
ACTRN012605000665639; http://www.actr.org.au/), which has
been described previously in detail.8 Ethics Committees from
each participating centre approved the study and informed care-
giver consent was given before enrolment.
Eligible infants were aged less than 6 months and diagnosed
with ‘classic’ CF (at least two of the following: two CF muta-
tions, sweat chloride >60 mmol/litre, pancreatic insufﬁciency or
meconium ileus) subsequent to newborn screening in the
Australian states of New South Wales (NSW), Queensland,
South Australia (SA) and Victoria, and throughout New Zealand
(NZ) between June 1999 and April 2005 inclusive.
In brief, this was a clinical trial in which infants were ran-
domly assigned in a 1 : 1 ratio, stratiﬁed by site (Australian state
or NZ) and gender, to receive either bronchoalveolar lavage
(BAL)-directed therapy or standard management from under
6 months of age until 5 years of age. A routine clinic review was
undertaken at least every 3 months. Infants recruited in two
states (NSWand SA) only were prescribed antibiotic prophylaxis
(ﬂucloxicillin) during their ﬁrst year of life.
Respiratory exacerbations were deﬁned as ‘any change in
respiratory symptoms from baseline’ to try and capture all epi-
sodes as far as possible. These were documented on a standar-
dised questionnaire with all the parameters making up the
individual episode, and reported by either family alone or
family and physician at clinic visits when an oropharyngeal
swab was taken. Hospital admission occurred if the oropharyn-
geal swab grew Pseudomonas aeruginosa, or the treating phys-
ician deemed it necessary because of illness severity, or failure to
improve after 6 weeks of community treatment. Otherwise, chil-
dren were managed at home (community management) where
initially ﬂucloxicillin was increased (prophylactic group) or pre-
scribed (non-prophylactic group) and/or a second oral
(non-anti-pseudomonal) antibiotic was added or substituted
depending on the culture results and individual tolerance. All
children were treated identically to this point. However, if hos-
pital admission ensued, the BAL group underwent bronchos-
copy and received intravenous antibiotics if the BAL culture was
positive for P aeruginosa or if deemed necessary clinically, while
those in the standard group received intravenous antibiotics
regardless.8
P aeruginosa in the oropharyngeal sample (standard group) or
at ≥103 colony forming units CFU/ml in BAL ﬂuid (BAL group)
resulted in 2 weeks of intravenous ticarcillin clavulanate or cefta-
zidime and tobramycin, followed by 2 months of inhaled tobra-
mycin (TOBI 300 mg/5 ml) with 1 month of oral ciproﬂoxacin.
At treatment end children either underwent a further BAL (BAL
group) or had oropharyngeal swabs taken (standard group). If P
aeruginosa persisted the eradication course was repeated and if
follow-up cultures were still positive the child was deemed
‘chronically infected’.
Procedures
BAL under general anaesthesia, and BAL and oropharyngeal cul-
tures were performed as described previously.8 All children
underwent additional assessments at age 5 years, including phys-
ical examination, anthropometric evaluation, oropharyngeal and
BAL cultures, chest CT scans and spirometry.8 Lung function
was measured post bronchodilatation using American Thoracic
Society criteria.9
Analysis
Standardised questionnaires were completed for visits at ‘ran-
domisation’, for ‘routine reviews’, ‘exacerbations’ and ‘exacerba-
tion reviews’. Exacerbation duration was estimated from the
dates recorded on the ‘exacerbation’ and ‘exacerbation review’
forms and when necessary the hospital discharge or end of
study date.
Bronchiectasis and air trapping on chest CT scans, interpreted
blinded to clinical data, were dichotomised into either being
present or absent. Z scores were calculated for weight using the
2000 CDC Growth Reference Charts (http://www.cdc.gov/
growthcharts); forced expiratory volume in 1 s (FEV1) using
British reference values (http://www.lungfunction.org/
growinglungs); and respiratory rate counted over 1 min by using
published age-related standards.10
Group comparisons are presented with 95% CI and two-
sided p values with logistic regression used to estimate OR for
dichotomous outcomes and t tests or linear regression for mean
comparisons with continuous outcomes. Skewed data under-
went logarithmic transformation with medians and IQR pre-
sented. Incidence of exacerbations is summarised as a rate per
person-years of follow-up time (stratiﬁed by age, randomised
treatment group, gender, site, prophylaxis, P aeruginosa infec-
tion ‘ever’, maternal smoking and parental education level).
Incidence rate ratios were estimated using Poisson regression
analysis, with allowance for over-dispersion attributable to vari-
ation between patients. For regression analyses of associations
between exacerbation rates and later outcomes, incidence rates
were transformed to log base 2 where exacerbation rate was the
explanatory variable, while natural logs were used when exacer-
bation rate was the outcome variable (years 4 and 5). The
former scaling meant that regression coefﬁcients and OR repre-
sented expected change in outcome per doubling of early-life
exacerbation rate, while the latter produced the standard log-
based interpretation of expected change in outcome in percent-
age terms relative to small differences in predictor values.11
When comparisons involved repeated measures from the same
patient, standard errors allowing for clustering effects were cal-
culated using the robust ‘information sandwich’ method.
Analysis was performed using Stata V.12.1.
RESULTS
Overall, 170 children were enrolled (86 to standard group, 84
receiving allocated intervention, and 84 to the BAL group) at
a mean age of 3.6 (SD 1.6) months with 157 (77 standard
group and 80 BAL group, 92% of the total) completing the
study.8
There were 2080 respiratory exacerbations in 166 children
(range 0–29 per child), an incidence rate of 3.66 episodes per
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person-year. Of these, 1667 (80.1%) in 164 children were com-
munity managed (93.4% had antibiotics) and 413 (19.9%) in
133 children required hospitalisation. The median duration was
22 days (IQR 14–38) for community-managed exacerbations
and 50 days (IQR 26–85) for hospital-admission episodes
(p<0.001). Longer duration was also seen in those with a
history of P aeruginosa ‘ever’ (median 28 days, IQR 15–50)
versus those from whom it had never been isolated (median
22 days, IQR 14–42, p=0.002).
On average, the exacerbation rate increased by 9% (95% CI
4% to 14%; p<0.001) per year of age and there was an associ-
ation between site and both total and ‘doctor reported’ exacer-
bations (table 1). Similarly, children who received early
antibiotic prophylaxis had lower exacerbation rates over the
whole study period than those without prophylaxis. This prac-
tice was determined by site, so the apparent effect of prophy-
laxis cannot be separated from other factors that might have
differed between sites. No evidence for differences in total
exacerbation rates was observed by randomised treatment group
(BAL vs standard), gender or home environment (maternal
smoking or parental education levels). There was a trend
towards a higher rate among those ever positive for P aerugi-
nosa, and a history of a positive P aeruginosa culture was the
only factor clearly associated with increased risk of hospital
admission for a respiratory exacerbation (table 1). The latter is
not surprising as a positive culture triggered hospitalisation for
eradication treatment.
Of the 2080 reported exacerbations, parents reported 2069
and a doctor review was undertaken in 1263 (61%) of these epi-
sodes (ﬁgure 1). For parental responses, the presence of cough,
nocturnal cough, and wheeze was signiﬁcantly more common in
children managed in hospital. For doctor-reviewed
exacerbations, cough, wheeze, tracheal tug and/or chest wall
recession, and auscultatory crackles were signiﬁcantly more fre-
quent in episodes requiring hospital admission. Children admit-
ted with P aeruginosa prompted by an oropharyngeal or BAL
sample but no new symptoms or signs did not have an exacerba-
tion form ﬁlled out and are not included here. There were 32
admissions for P aeruginosa treatment outside of an exacerbation
in 20 children. Associations between exacerbations in the ﬁrst
5 years of life and lung structure and function, and
weight-for-age z scores at age 5 years are presented in tables 2
and 3. Outcomes at 5 years were consistently worse in children
who ever had an exacerbation requiring hospital admission.
There was evidence of an increased risk of bronchiectasis on
chest CT scans, slightly weakened after adjusting for
P aeruginosa isolation ever (which triggered admission, table 2).
The rate of exacerbations during the ﬁrst 2 years of life was asso-
ciated with a lower FEV1, even after adjusting for a history of P
aeruginosa infection (table 2, ﬁgure 2). Table 3 shows the asso-
ciations between 5-year outcomes and reporting of speciﬁc
symptoms during exacerbations (‘ever’ vs ‘never’ reported).
Unsurprisingly, the chance of a symptom ever being reported
during an exacerbation increased with the number of exacerba-
tions experienced. Worse outcomes were generally seen with
higher doctor reporting of symptoms on exacerbations. This was
particularly striking for FEV1 z-score values and doctor recorded
chest wall retractions and/or tracheal tug, but also signiﬁcant for
high-resolution CT scan bronchiectasis and wheeze, and weight
z score with retractions and wheeze. The only statistically strong
association with parent reporting of symptoms was with air trap-
ping and parent-reported wheeze. Finally, exacerbation rates
during years 4 and 5 increased by 12% for each doubling of the
exacerbation rate in the ﬁrst 2 years of life (ﬁgure 3).
Figure 1 Features of respiratory exacerbations according to whether ‘community managed’ or ‘hospital admission’. 1Respiratory rate z score more
than 2 SDs from the mean.10
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DISCUSSION
This is the ﬁrst prospective study to record community and hos-
pital managed respiratory exacerbations and their association
with chest CT scan and lung function outcomes in children with
CF diagnosed through newborn screening and followed to age
5 years. The children were participants in a RCT comparing
BAL-directed versus standard therapy in which no differences
between treatment groups were observed for the primary out-
comes at 5 years of age for P aeruginosa infection and structural
lung injury on CT scans.8 Children had on average three to four
exacerbations per year, with episodes increasing with each year
of life. At 5 years the overall exacerbation rate in the ﬁrst
2 years of life was associated with lower FEV1 values, while
hospital-admission exacerbations were associated with increased
risk of bronchiectasis and lower weight-for-age z scores.
Despite lacking a validated deﬁnition,12 exacerbations are
being used widely as trial outcome measures, variably recorded
as exacerbation rate,13 14 time to exacerbation,14 15 or time to
resolution.16 ‘Exacerbations’ avoid the disadvantages seen with
other single outcome measures, such as spirometry or CT scans
in this young age group, and can be documented in community
and clinic settings.
Overall, we recorded 3.66 exacerbations per child-year
throughout the ﬁrst 5 years of life with no differences between
treatment groups or gender, but with a signiﬁcant increase in
exacerbation rates with age. Differences were reported between
study sites, and a signiﬁcant reduction was seen in children
receiving anti-staphylococcal antibiotic prophylaxis up to at
least 12 months of age. In contrast, prospective birth cohort
studies of healthy Australian children report 4.1–6.2 acute
respiratory infections per child in the ﬁrst 1–2 years of life,17 18
with rates falling to two per year by age 5 years, and an overall
rate during this period of 3.4 respiratory illnesses per child-year,
which is similar to our CF cohort.19
Despite using a broad deﬁnition, the reported exacerbation
rate was lower than expected in these infants with CF, and we
have considered possible explanations. First, we could have
missed events before enrolment and throughout the study.
However, the ﬁrst respiratory illness in the birth cohort studies
was reported between 4.2 and 6 months, and our mean enrol-
ment age was 3.6 months. Additionally, we reviewed children
with CF at least 3 monthly and more frequently when families
required greater support, as during infancy or when determining
exacerbation resolution. Consequently, events missed were likely
to be mild as these caregivers were well educated at recognising
and acting upon new respiratory symptoms. Second, while
exacerbations were less frequent, their duration of 22
(community-managed) and 50 (hospital-managed) days was
greater than the 4–14 days reported in healthy children.18 20
Comparisons of CF and non-CF siblings have also found that
although their respiratory infection rates were similar, CF siblings
had longer symptom duration and greater lower respiratory tract
involvement.21 Third, higher infection rates in early childhood
are associated with household crowding, formula feeding, low
immunisation rates, passive smoking and poor nutrition, with the
greatest number of respiratory infections (up to nine per year)
reported in studies of healthy children attending daycare.17 22
Having received a life-limiting diagnosis for their child, some of
these factors could be improved or eliminated by a motivated
family. Interestingly, a recent study examining the effects of
inhaled hypertonic saline on respiratory exacerbation rates in
young children with CF (ISIS) reported even lower rates
(2.3 events/year), although based on a more stringent deﬁnitionT
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including the need for antibiotic treatment. We have re-examined
the total exacerbations reported in our study and determined
that 90.4% would have also met the ISIS study criteria.23
A lower exacerbation rate with anti-staphylococcal antibiotic
prophylaxis was an interesting ﬁnding. A Cochrane review
found that this approach reduced Staphylococcus aureus
culture rates, but importantly not hospitalisation or antibiotic
use.24 Our study was not designed to address this issue and
prophylaxis was determined by research sites where
signiﬁcantly lower exacerbation rates were recorded. Knowing
children were already taking antibiotics may have resulted in a
higher threshold for reporting symptoms or caregivers simply
Table 3 Associations between 5-year outcomes and reporting of specific symptoms/signs during exacerbations
Outcome Symptom
Symptom ever
reported
Symptom never
reported OR 95% CI p Value
Parent-reported symptoms
Bronchiectasis on CT scan (n=153) Wheeze 57% (62/108) 56% (25/45) 1.08 0.53 to 2.17 0.83
Fever 56% (75/133) 60% (12/20) 0.86 0.33 to 2.25 0.76
Air trapping on CT scan (n=154) Wheeze 54% (59/110) 25% (11/44) 3.47 1.59 to 7.56 0.002
Fever 43% (58/134) 60% (12/20) 0.51 0.20 to 1.33 0.17
FEV1 z score* (n=128) n Mean SD n Mean SD Diff in means 95% CI p Value
Wheeze 98 −0.55 1.19 30 −0.13 1.08 −0.43 −0.91 to 0.06 0.08
Fever 112 −0.48 1.18 16 −0.26 1.19 −0.22 −0.84 to 0.41 0.49
Weight z score† (n=157)
Wheeze 111 −0.24 0.85 46 −0.03 0.84 −0.21 −0.50 to 0.09 0.16
Fever 135 −0.14 0.85 22 −0.45 0.80 0.31 −0.07 to 0.70 0.11
Doctor-reported symptoms
Bronchiectasis on CT scan (n=153) Wheeze 67% (43/64) 49% (44/89) 2.09 1.07 to 4.08 0.03
Crackles 62% (34/55) 54% (53/98) 1.37 0.70 to 2.70 0.36
Chest retractions 59% (36/61) 55% (51/92) 1.16 0.60 to 2.23 0.66
Air trapping on CT scan (n=154) Wheeze 51% (33/65) 42% (37/89) 1.45 0.76 to 2.76 0.26
Crackles 55% (30/55) 40% (40/99) 1.77 0.91 to 3.44 0.09
Chest retractions 53% (32/60) 40% (38/94) 1.68 0.88 to 3.24 0.12
FEV1 z score* (n=128) n Mean SD n Mean SD Diff in means 95% CI p Value
Wheeze 54 −0.60 1.26 74 −0.34 1.11 −0.25 −0.67 to 0.16 0.23
Crackles 44 −0.68 1.32 84 −0.33 1.09 −0.34 −0.77 to 0.09 0.12
Chest retractions 51 −0.80 1.30 77 −0.22 1.03 −0.59 −1.00 to −0.18 0.005
Weight z score† (n=157)
Wheeze 66 −0.34 0.86 91 −0.07 0.82 −0.27 −0.54 to 0.00 0.05
Crackles 55 −0.20 0.80 102 −0.17 0.88 −0.03 −0.31 to 0.25 0.85
Chest retractions 62 −0.37 0.88 95 −0.06 0.81 −0.31 −0.58 to −0.04 0.02
*FEV1 z score determined from normal values (http://www.lungfunction.org/growinglungs).
†Weight z-score determined from normal values (http://www.cdc.gov/growthcharts).
Diff in means, difference in means; FEV1, forced expiratory volume in 1 s; SD, standard deviation.
Figure 3 Rate of respiratory exacerbations in years 4 and 5 versus
years 1 and 2 of life. Eleven and two patients reported 0 exacerbations
in years 1 and 2, and 4 and 5, respectively. These are shown in the
log-scale graph with a value of 0.28 or 0.23, which is the log of half
the smallest observed rate in each pair of years.
Figure 2 Forced expiratory volume in 1 s (FEV1) z score versus
respiratory exacerbation rate during the ﬁrst 2 years of life. Six patients
reported 0 exacerbations in the ﬁrst 2 years of life. These are shown in
the log-scale graph with a value of 0.28, which is the log of half the
smallest observed rate.
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increasing the dose without reporting this at subsequent
reviews.
Our study deﬁnition of ‘exacerbation’ avoided the need for
either antibiotic treatment or medical review, thereby attempting
to capture as many episodes as possible. The presence of cough,
wheeze, chest wall recession and auscultatory crackles was sig-
niﬁcantly more common in exacerbations requiring hospital
admission but no single feature was able to reliably predict this
course. Although several scoring systems have been developed,
these have been mainly for older children and adults,12 25–27
those chronically infected with P aeruginosa,12 requiring hos-
pital treatment26 or included spirometery.26 The ‘Acute
Respiratory Illness Checklist’ was developed to evaluate a candi-
date respiratory syncytial virus vaccine in 34 children with CF
aged 1.6–7.9 years.28 This required at least three parameters for
upper and ﬁve parameters for lower respiratory infections. The
need for a standardised deﬁnition of a respiratory exacerbation
was ﬁrst recommended in 1994, and now another is required
speciﬁcally for infancy and early childhood.29
We found a statistically signiﬁcant association between exacer-
bations requiring hospitalisation and bronchiectasis in the 5
years of age high-resolution CT scan. Exacerbations are asso-
ciated with disease progression in older age groups with CF.2 4
Of interest, in 61 children aged 6–10 years, CT scans performed
at baseline prior to a rhDNAse trial showed that ‘total’, ‘bron-
chiectasis’ and ‘mucous plugging’ scores correlated signiﬁcantly
with respiratory exacerbation rate. The change in scores with
chest CT scans 2 years later also correlated with respiratory
exacerbations, most strongly with bronchiectasis.30 The AREST
CF group also reported the presence and extent of bronchiec-
tasis increased from 8.5% in the ﬁrst year to 36% by age 4 years
in 96 children with CF and was associated with P aeruginosa
infection, but not hospitalised days for respiratory illness.31
The exacerbation rate in the ﬁrst 2 years of life was associated
with reduced FEV1 at age 5 years, which remained when adjust-
ing for P aeruginosa infection. In contrast, in the rhDNAse
study lung function parameters did not correlate with the
number of respiratory infections at baseline or over the 2-year
study period.30 However, two further studies reported an associ-
ation between respiratory symptoms and lower lung function in
young children with CF during stable health.32 33 Moreover, in
37 infants, a greater decline was reported in forced vital capacity
and FEV0.5 across a 1-year or 2-year period when neutrophil
elastase, S aureus or P aeruginosa were present in contemporan-
eous BAL cultures.34 As new P aeruginosa infection triggered
hospitalisation, we cannot comment on this effect in our study.
Exacerbations requiring hospital admission resulted in lower
weight-for-age z scores at age 5 years, while parent-reported
wheeze predicted air trapping on CT scans and doctor-reported
chest wall retractions predicted a lower FEV1 score. Finally, the
data suggested that children with higher rates of respiratory
exacerbations in the ﬁrst 2 years of life continued to experience
higher rates in years 4 and 5. This is consistent with prospective
studies in healthy children that described tracking of high-
respiratory infection rates in infancy into older age groups and
this may be a marker for more severe disease progression.17 20
In conclusion, this prospective study following children diag-
nosed with CF subsequent to newborn screening to age 5 years
found a respiratory exacerbation rate of 3.66 episodes per child-
years. On average the exacerbation rate increased by 9% per year
of age. While certain clinical features were seen more often in
severe exacerbations, no single parameter reported by either
parents or doctors predicted the need for hospital admission.
Higher exacerbation rates in the ﬁrst 2 years of life resulted in a
lower FEV1 and higher exacerbations rates in later years, and
exacerbations requiring hospital admission were associated
with bronchiectasis and lower weight-for-age z scores at 5 years.
These ﬁndings emphasise the importance of pulmonary exacerba-
tions in the ﬁrst years of life. They also raise the possibility of dif-
ferent disease mechanisms operating. Repeated mild-to-moderate
exacerbations managed in the community may result in airway
remodelling, while more severe hospitalised episodes could
increase structural airway injury risk. Further studies are required
to identify whether such differences exist and whether these
should be considered when introducing novel treatments to reduce
early CF lung injury.
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